In this interview, Dr. Maria Gion, of Hospital Universitario Ramón y Cajal, Madrid, discusses the ATRACTIB trial, which evaluated a triplet regimen of paclitaxel, atezolizumab, and bevacizumab in patients with advanced triple-negative breast cancer (TNBC), including those with PD-L1–negative tumors.
Advertisement
Study shows HCV-related sicca differs from Sjögren’s, supporting their classification as separate diseases.
Dialysis is not right for all patients. Here's what to consider when weighing dialysis vs conservative kidney management.
Dialysis facilities with more commercially insured patients beat mortality rates of those serving more Medicare patients.
A new study highlights rising hepatitis E cases in older adults, with widening global disparities.
Probiotics improved IBS symptoms, reduced inflammation, and boosted gut barrier health across IBS subtypes.
Safi Biotherapeutics expects to initiate a clinical trial in 2027 following completion of IND-enabling activities.
Dr. Iyengar explains how metabolic health impacts cancer risk, treatment response, and outcomes across multiple tumor types.
Dietitian Jessica Strawn helps bust some common nutrition myths for patients with CKD.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
Safi Biotherapeutics expects to initiate a clinical trial in 2027 following completion of IND-enabling activities.
The primary end point for RBC transfusion independence was not met but the cohort still had significant anemia improvement.
Oral avatrombopag shows promise in kids with ITP, offering a safer, effective alternative to current treatments.
Researchers also measured in the study cohort a very high discontinuation rate for this agent.
In a cohort of adults and adolescents marstacimab produced bleed control superior to that from on-demand bypassing agent.
The agent notably in preclinical studies has accomplished increased HbF without any evident cytotoxicity.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.